0
Skip to Content
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Home
Agenda
Venue & Accommodation
Folder: Previous years
Back
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW

How to evaluate drug effectiveness in migraine?

Session 0: Opening lecture

Andrea Cipriani


MD PhD, Professor of Psychiatry, Department of Psychiatry, University of Oxford

Download presentation

Next

The role of inflammation in migraine and its clinical impact

You Might Also Like

Related Embedded Video Item Thumbnail Should we treat during the prodromal phase? Con
Related Embedded Video Item Thumbnail The role of inflammation in migraine and its clinical impact
Related Embedded Video Item Thumbnail Switching between anti-CGRP monoclonal antibodies and gepants
Related Embedded Video Item Thumbnail Migraine biomarkers in biofluids
Related Embedded Video Item Thumbnail The nurse, the backbone of medical care

Privacy policy

Teva Privacy Notice |Teva Pharmaceuticals

Legal Notes | Teva Pharmaceuticals

Accessibility Statement

Teva code of conduct


Norway, Finland, Denmark: AJO-DK-NP-00128